| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(00)00006-2 |
| P698 | PubMed publication ID | 10738097 |
| P2093 | author name string | Cryz SJ | |
| Lesmana MM | |||
| Levine MM | |||
| O'Hanley PP | |||
| Pandam SS | |||
| Peetosutan KK | |||
| Punjabi NH | |||
| Richie EE | |||
| Sidharta YY | |||
| Simanjuntak CH | |||
| Sukandar MM | |||
| Wangsasaputra FF | |||
| Wasserman SS | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Indonesia | Q252 |
| cholera | Q12090 | ||
| vaccine | Q134808 | ||
| P304 | page(s) | 2399-2410 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area | |
| P478 | volume | 18 |
| Q44533423 | A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection |
| Q37358603 | A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh |
| Q79815991 | A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice |
| Q41986831 | A randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single ≥2x108 colony forming units [cfu] standard-dose versus a ≥2x109 cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccin |
| Q36904890 | Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy |
| Q35916527 | Acute, infectious diarrhea among children in developing countries |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q34067874 | Bacterial interplay at intestinal mucosal surfaces: implications for vaccine development |
| Q24536068 | Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity |
| Q35802777 | Can oral cholera vaccination play a role in controlling a cholera outbreak? |
| Q47794110 | Causes of impaired oral vaccine efficacy in developing countries. |
| Q55878773 | Cholera |
| Q55890255 | Cholera |
| Q35564879 | Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection |
| Q79817917 | Cholera vaccines |
| Q30235247 | Cholera. |
| Q57164819 | Cholera: Immunity and Prospects in Vaccine Development |
| Q34297930 | Cofactors that may influence vaccine responses |
| Q57311216 | Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias |
| Q38683902 | Correlates of protection for enteric vaccines |
| Q43369067 | Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs |
| Q26823170 | Critical analysis of compositions and protective efficacies of oral killed cholera vaccines |
| Q37640110 | Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. |
| Q52650640 | Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. |
| Q39869578 | Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding |
| Q35896020 | Enteric pathogens as vaccine vectors for foreign antigen delivery |
| Q73816620 | Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits |
| Q35137102 | Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries |
| Q38979270 | Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine |
| Q44133395 | Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase |
| Q37002887 | Exploiting cholera vaccines as a versatile antigen delivery platform |
| Q92339205 | Factors That Influence the Immune Response to Vaccination |
| Q93090575 | Fishing for vaccines against Vibrio cholerae using in silico pan-proteomic reverse vaccinology approach |
| Q38059916 | Immune responses and protection in children in developing countries induced by oral vaccines |
| Q89555434 | Immune system development varies according to age, location, and anemia in African children |
| Q36898523 | Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. |
| Q37340450 | Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length |
| Q47345249 | Immunogenicity of Vibrio cholerae outer membrane vesicles secreted at various environmental conditions |
| Q33424453 | Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh |
| Q36837152 | Implication of nanoparticles/microparticles in mucosal vaccine delivery |
| Q30151668 | Improving immunization approaches to cholera |
| Q36227993 | Induction of interleukin-8 in T84 cells by Vibrio cholerae. |
| Q41426133 | Insights from natural infection-derived immunity to cholera instruct vaccine efforts |
| Q45129797 | Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera |
| Q45958574 | Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. |
| Q34578596 | Issues in the design and implementation of vaccine trials in less developed countries |
| Q33849731 | Lessons from cholera & Vibrio cholerae. |
| Q36600341 | Live attenuated oral cholera vaccines |
| Q33578033 | Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines |
| Q37410387 | Memory T-cell responses to Vibrio cholerae O1 infection |
| Q34409172 | Mucosal immunity and vaccines |
| Q37559647 | Mucosal vaccines: novel advances in technology and delivery |
| Q40695423 | New developments in the understanding of cholera |
| Q37956429 | New insights in mucosal vaccine development. |
| Q37953796 | New-generation vaccines against cholera |
| Q36489754 | Oral cholera vaccines: use in clinical practice |
| Q24235775 | Oral vaccines for preventing cholera |
| Q51150718 | PaxVax CVD 103-HgR single-dose live oral cholera vaccine. |
| Q36530216 | Postgenomic approaches to cholera vaccine development |
| Q36670147 | Production and sequence validation of a complete full length ORF collection for the pathogenic bacterium Vibrio cholerae |
| Q34203915 | Protective effect of natural rotavirus infection in an Indian birth cohort |
| Q37363974 | Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis |
| Q84066281 | Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response |
| Q34121025 | Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine |
| Q34002698 | Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination |
| Q40045437 | Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus |
| Q35547754 | Review of oral cholera vaccines: efficacy in young children |
| Q39255393 | Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective |
| Q50111881 | Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. |
| Q37544964 | Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. |
| Q39708963 | Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. |
| Q36915108 | Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. |
| Q41682935 | T cell up-regulation of CD127 is associated with reductions in the homeostatic set point of the peripheral T cell pool during malnourishment |
| Q42062729 | TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups |
| Q36688241 | The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine |
| Q34377076 | The WHO Vaccine Trial Registry |
| Q24812819 | The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance |
| Q38120924 | The state-of-the-art of approved and under-development cholera vaccines |
| Q36856016 | The true burden and risk of cholera: implications for prevention and control |
| Q34757562 | Transcriptional responses of intestinal epithelial cells to infection with Vibrio cholerae |
| Q35867213 | Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice |
| Q35073915 | Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice |
| Q35778973 | Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers |
| Q42572423 | Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO. |
| Q33808779 | Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. |
| Q28080866 | Vaccines against enteric infections for the developing world |
| Q33578045 | Vaccines against human diarrheal pathogens: current status and perspectives |
| Q26824128 | Vaccines for low-income countries |
| Q26995690 | Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus |
| Q27004488 | Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae |
| Q34562952 | Vibrio cholerae: lessons for mucosal vaccine design |
| Q27489979 | Wanted, dead or alive: New viral vaccines |
| Q35047232 | When can a clinical trial be called 'randomized'? |
Search more.